APA (7th ed.) Citation

Peng, X., & Liu, J. (2025). Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: Protocol for a systematic review and network meta-analysis. Frontiers in medicine, 12, 1539880. https://doi.org/10.3389/fmed.2025.1539880

Chicago Style (17th ed.) Citation

Peng, Xiaolian, and Jie Liu. "Poly-ADP Ribose Polymerase (PARP) Inhibitor Regimens for Platinum-sensitive Ovarian Cancer in Randomized, Double-blind, Phase III Controlled Trials: Protocol for a Systematic Review and Network Meta-analysis." Frontiers in Medicine 12 (2025): 1539880. https://doi.org/10.3389/fmed.2025.1539880.

MLA (9th ed.) Citation

Peng, Xiaolian, and Jie Liu. "Poly-ADP Ribose Polymerase (PARP) Inhibitor Regimens for Platinum-sensitive Ovarian Cancer in Randomized, Double-blind, Phase III Controlled Trials: Protocol for a Systematic Review and Network Meta-analysis." Frontiers in Medicine, vol. 12, 2025, p. 1539880, https://doi.org/10.3389/fmed.2025.1539880.